October 14, 2021
FDA Awards 11 Grants to Clinical Trials to Develop New Medical Products for Rare Disease Treatments
Read MoreNovember 11, 2020
1st Patient Treated in Phase 3 Trial of RDEB Gene Therapy, D-Fi
Read MoreOctober 29, 2020
Castle Creek Biosciences’ D-Fi To Be Manufactured At In-House cGMP
Read MoreOctober 20, 2020
First Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma
Read MoreMay 09, 2020
9 Philly Companies on the Cutting Edge of Cell and Gene Therapy Innovation
Read MoreJanuary 02, 2020
“Acquisition Combines Two Pipelines for Rare Skin Diseases” John Maslowski, CEO, Castle Creek Biosciences
Read More